PIPERAZINE DERIVATIVES AS CAV2.2 CALCIUM CHANNEL BLOCKERS
申请人:Norton David
公开号:US20140038976A1
公开(公告)日:2014-02-06
The invention relates to novel piperazine compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca
v
2.2 calcium channels is beneficial, i.e. in particular to treat pain.
[EN] PIPERAZINE DERIVATIVES AS CAV2.2 CALCIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE EN TANT QUE BLOQUEURS DE CANAUX CALCIQUES CAV2.2
申请人:CONVERGENCE PHARMACEUTICALS
公开号:WO2012098400A1
公开(公告)日:2012-07-26
The invention relates to novel piperazine compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.
Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
申请人:Norton David
公开号:US08933132B2
公开(公告)日:2015-01-13
The invention relates to novel piperazine compounds of formula (I):
to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.